Study of Safety and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH) (FLIGHT-FXR)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02855164 |
|
Recruitment Status :
Terminated
First Posted : August 4, 2016
Results First Posted : July 29, 2021
Last Update Posted : September 5, 2021
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Non-alcoholic Steatohepatitis (NASH) | Drug: Tropifexor (LJN452) Drug: Placebo | Phase 2 |
Part A In Part A, 77 subjects were randomized at baseline to receive tropifexor (10 μg, 30 μg, 60 μg or 90 μg) or placebo (Arms A, B, C, D and E) for 12 weeks. After ≥ 90% of the subjects from Part A completed 8 weeks of treatment, the first interim analysis of all Part A data was performed and the Data Monitoring Committee (DMC) recommended evaluation of 90 μg tropifexor (safe andefficacious) in Part B. The treatment arms of Part A were completed through Week 16 without adaptation.
Part B Randomization for Part B was started after the DMC recommendations on the dose to be used in Part B were implemented by the sponsor. As planned in the study protocol, since the first interim analysis selected one active dose (90 μg) to be tested in Part B, one of the other originally planned active treatment arms (60 μg) was included with a smaller sample size to confirm the earlier findings of this dose observed in Part A. Therefore, in Part B, 121 subjects, were randomized at baseline to receive tropifexor (90 μg and 60 μg) or placebo (Arms F, G and H) for 12 weeks.
Part C was introduced as a result of the DMC recommendation to pursue doses > 90 μg. Randomization in Part C started once the Part B randomization was completed. In Part C, 152 subjects were randomized at baseline to receive 140 μg or 200 μg tropifexor or placebo (Arms I, J and K) for 48 weeks.
One patient was treated at 2 sites but is still only one patient. 350 total enrollment, and not 351.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 350 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Intervention Model Description: | This was a randomized, double-blind, placebo-controlled, multicenter, parallel-group, dose finding, 3-part (Parts A, B, and C), adaptive design study to assess the safety, tolerability, and efficacy of six doses of tropifexor as compared to placebo in subjects with NASH. Each study part had a screening period followed by a double-blind, randomized, treatment period, and a post-treatment follow-up period. This study was extended based on safety and efficacy results in Part A and available long-term toxicology coverage; Part C was added to explore 48 weeks of treatment at higher doses with paired biopsies in F2/3 NASH patients. |
| Masking: | Triple (Participant, Care Provider, Investigator) |
| Primary Purpose: | Treatment |
| Official Title: | A Randomized, Double-blind, Placebo Controlled, 3- Part, Adaptive Design, Multicenter Study to Assess Safety, Tolerability and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH): FLIGHT-FXR |
| Actual Study Start Date : | August 1, 2016 |
| Actual Primary Completion Date : | April 6, 2020 |
| Actual Study Completion Date : | April 6, 2020 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: LJN452 10 μg
Tropifexor (LJN452) Part A
|
Drug: Tropifexor (LJN452)
Comparison of different doses of drug |
|
Experimental: LJN452 30 μg
Tropifexor (LJN452) Part A
|
Drug: Tropifexor (LJN452)
Comparison of different doses of drug |
|
Experimental: LJN452 60 μg
Tropifezor (LJN452) Parts A + B
|
Drug: Tropifexor (LJN452)
Comparison of different doses of drug |
|
Experimental: LJN452 90 μg
Tropifexor (LJN452) Parts A + B
|
Drug: Tropifexor (LJN452)
Comparison of different doses of drug |
|
Placebo Comparator: Placebo A+ B
Placebo Parts A + B
|
Drug: Placebo
Comparator |
|
Experimental: LJN452 140 μg
Tropifexor (LJN452) Part C
|
Drug: Tropifexor (LJN452)
Comparison of different doses of drug |
|
Experimental: LJN452 200 μg
Tropifexor (LJN452) Part B
|
Drug: Tropifexor (LJN452)
Comparison of different doses of drug |
|
Placebo Comparator: Placebo C
Placebo Part C
|
Drug: Placebo
Comparator |
- Number of Nonalcoholic Steatohepatitis (NASH) Patients With Treatment Emergent Adverse Events (TEAE) [ Time Frame: End of Treatment (EoT): For Parts A&B, EoT was Week 12 (Primary Outcome Measure). For Part C, EoT was Week 48 (Secondary Outcome Measure) ]Number of Nonalcoholic steatohepatitis (NASH) patients with TEAEs
- Change in Transaminase Levels (ALT) [ Time Frame: End of Treatment (EoT): For Parts A&B, EoT was Week 12 (Primary Outcome Measure). For Part C, EoT was Week 48 (Secondary Outcome Measure) ]
The alanine aminotransferase (ALT) test is a blood test that checks for liver damage. High levels of ALT may indicate liver damage. Normal range for ALT is typically 10 to 45 U/L or so (varies a little by age and gender). Elevation of these values indicate more liver inflammation/damage.
ALT elevation is not unexpected in this patient population
Dose relationship of tropifexor (LJN452) on ALT marker of hepatic inflammation in NASH from baseline to week 12
Summary statistics of change in ALT from baseline to EOT by treatment
- Change in Aspartate Transaminase (AST) [ Time Frame: End of Treatment (EoT): For Parts A&B, EoT was Week 12 (Primary Outcome Measure). For Part C, EoT was Week 48 (Secondary Outcome Measure) ]
To determine the dose relationship of tropifexor (LJN452) on markers of hepatic inflammation (AST) in NASH from baseline to Week 12 The alanine aminotransferase (AST) test is a blood test that checks for liver damage. High levels of AST may indicate liver damage. Normal range for AST is typically 10 to 45 U/L or so (varies a little by age and gender). Elevation of these values indicate more liver inflammation/damage
AST elevation is not unexpected in this patient population
The aspartate aminotransferase (AST) test is a blood test that checks for liver damage. Higher levels indicate more possible liver damage
Summary statistics of change in AST from baseline up to end of treatment (EOT)
- Change From Baseline in % of Fat in the Liver Assessed Using Magnetic Resonance Imaging (MRI) [ Time Frame: End of Treatment (EoT): For Parts A&B, EoT was Week 12 (Primary Outcome Measure). For Part C, EoT was Week 48 (Secondary Outcome Measure) ]Repeated measures analysis: Relative change in percentage of fat in the liver assessed using MRI from baseline by visit up to EOT (Full analysis set)
- Change From Baseline in Weight [ Time Frame: 48 weeks ]Repeated measures for LS mean change in weight after 12 weeks of treatment
- Change in Body Mass Index (BMI) [ Time Frame: 12 weeks ]Repeated measures for the LS mean change in BMI after 12 weeks of treatment. Body mass index (BMI) is a measure of body fat based on height and weight
- Change From Baseline in Waist to Hip (WTH) Ratio [ Time Frame: 12 weeks ]The LS mean change in waist to hip ratio after 12 weeks of treatment
- Change From Baseline in Biomarker FGF19 [ Time Frame: baseline, week 6 ]
Dose-response relationship of tropifexor (LJN452) on FGF19 over time, a marker of FXR target engagement in the gut.
ANCOVA: Ratio of FGF19 (pg/mL) post-dose to pre-dose at Week 6
Value at 6 weeks minus value at baseline
- Change From Baseline in Biomarker C4 [ Time Frame: Week 6, 4 hours post dose ]
Dose-response relationship of LJN452 on C4, a marker of hepatic target engagement at 4 hours post dose
C4 (ng/mL): Summary statistics by treatment and visit
- Change From Baseline on Markers of Liver Fibrosis, Fibroscan [ Time Frame: End of Treatment (EoT): For Parts A&B, EoT was Week 12. For Part C, EoT was Week 48 ]
Dose-response relationship of tropifexor (LJN452) on markers of liver fibrosis commonly available such as Fibroscan®
Liver stiffness (kPa): Summary statistics by treatment and visit
FibroScan is a specialized ultrasound machine for measuring fibrosis (scarring) in the liver
Scores range from 0-4 with zero being no liver scarring and 4 being advanced liver scarring (cirrhosis)
- Change From Baseline on Markers of Liver Fibrosis Panel (ELF) Score [ Time Frame: End of Treatment (EoT): For Parts A&B, EoT was Week 12. For Part C, EoT was Week 48 ]
ANCOVA: LS Mean Change in Enhanced liver fibrosis panel (ELF) score from baseline by visit up to EOT.
The total ELF score reference range calculated non-parametrically is 6.72 (90% CI 6.58-6.84) to 9.79 (90% CI 9.45-10.01); Journal of Hepatology 2013 vol. 59 j 236-242.
Enhanced liver fibrosis Test (ELF) panel: the following was assessed: hyaluronic acid (HA), tissue inhibitor of metalloproteinases (TIMP-1), and amino-terminal pro-peptide of procollagen type III (PIIINP).
The Enhanced Liver Fibrosis score is a linear combination of TIMP-1, PIIINP, and HA with the following formula: ELF score = 2.494+0.846 x ln(HA) + 0.735 x ln (PIIINP) + 0.391 x ln (TIMP-1).
- Change From Baseline on Markers of Liver Fibrosis, Fibrotest (Parts A+B) [ Time Frame: End of Treatment (EoT):12 weeks ]
Fibrosis biomarker test, originally called Fibrotest®/ Fibrosure®, is combines α2-macroglobulin (a2m), apolipoprotein A1 (aA1), total bilirubin (BIL), haptoglobin (h), GGT, and ALT. The coefficient for the score is calculated as: z = 4.467 x log(a2m) - 1.357 x log(h) + 1.017 x log(GGT) + 0.0281 x Age + 1.737 x log(BIL) - 1.184 x (aA1) + 0.301 x Gender - 5.54 where Gender = 1 for male and Gender = 0 for female. The score is then: 1/(1+e^-z).
Calculated scores range from 0.00 (no fibrosis) to 1.00 (severe fibrosis or cirrhosis) (See Part C in separate outcomes that follows)
- Change From Baseline on Markers of Liver Fibrosis, Fibrotest, (Part C) [ Time Frame: End of Treatment (EoT) was 48 weeks ]
Fibrosis biomarker test, originally called Fibrotest®/ Fibrosure®, is combines α2-macroglobulin (a2m), apolipoprotein A1 (aA1), total bilirubin (BIL), haptoglobin (h), GGT, and ALT. The coefficient for the score is calculated as: z = 4.467 x log(a2m) - 1.357 x log(h) + 1.017 x log(GGT) + 0.0281 x Age + 1.737 x log(BIL) - 1.184 x (aA1) + 0.301 x Gender - 5.54 where Gender = 1 for male and Gender = 0 for female. The score is then: 1/(1+e^-z).
Calculated scores range from 0.00 (no fibrosis) to 1.00 (severe fibrosis or cirrhosis)
- Change From Baseline on Gamma-glutamyl Transferase (GGT) [ Time Frame: EoT for Parts A+B=12 weeks; EoT for Part C = 48 weeks ]Summary statistics of change in GGT (IU/L) from baseline by visit up to EoT
- Change From Baseline on Fasting Lipid Profile [ Time Frame: End of Treatment (EoT): For Parts A&B, EoT was Week 12. For Part C, EoT was Week 48 ]Repeated measures analysis: LS geometric mean ratio of fasting lipids to baseline by visit up to EOT
- Itch Based on a Visual Analog Scale (VAS) Rating Scale [ Time Frame: EoT for Parts A+B=12 weeks; EoT for Part C = 48 weeks ]
Repeated measures analysis: Change in VAS for Itch from baseline by visit up to EoT
VAS score 0 = no disease; and 9 is severely advanced disease
- Pre-dose Trough Concentration (Ctrough) of LJN452 [ Time Frame: In Parts A and B, LJN452 Ctrough was measured on Study Days 7, 14, 28, 42, 56, and 84. In Part C LJN452 Ctrough was measured on Study Days 42, 84, 168, 280 and 336 ]Pre-dose Trough Concentration (Ctrough) of tropifexor (LJN452)
- C2h (Steady-state Drug Levels 2 Hours Postdose) of LJN452 [ Time Frame: Days 7 and 14 (10 and 30μg LJN452 C2h was not measured day 14) ]Summary C2h of tropifexor (LJN452)
- Biopsy-based Response at Week 48 Compared to Baseline: At Least One Point Improvement in Fibrosis (NASH CRN Staging) Without Worsening of Steatohepatitis (Part C) - Total Score [ Time Frame: EoT (Week 48) ]Number of patients who have at least one point improvement in fibrosis (NASH CRN staging) without worsening of steatohepatitis (total score)
- Biopsy-based Response at Week 48 Compared to Baseline: At Least One Point Improvement in Fibrosis (NASH CRN Staging) Without Worsening - FDA [ Time Frame: EoT (Week 48) ]Number of patients who have at least one point improvement in fibrosis (NASH CRN staging) without worsening of steatohepatitis (FDA)
- Biopsy-based Response at Week 48 Compared to Baseline: At Least One Point Improvement in Fibrosis (NASH CRN Staging) Without Worsening - EMA [ Time Frame: EoT (Week 48) ]Number of patients who have at least one point improvement in fibrosis (NASH CRN staging) without worsening of steatohepatitis (EMA)
- Biopsy-based Response at Week 48 Compared to Baseline: Difference Between Treatment Groups (Part C) - Resolution of Steatohepatitis (Diagnostic Category) [ Time Frame: EoT (Week 48) ]Resolution of steatohepatitis (diagnostic category) without worsening of fibrosis (NASH CRN staging)
- Biopsy-based Response at Week 48 Compared to Baseline: Difference Between Treatment Groups (Part C) - Resolution of Steatohepatitis (FDA, EMA) [ Time Frame: EoT (Week 48) ]Resolution of steatohepatitis (diagnostic category) without worsening of fibrosis (NASH CRN staging)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- male/female patients, 18 years or older
- written informed consent
- Part A and B patients : presence of NASH by histological evidence (liver biopsy obtained 2 years or less prior to randomization) with fibrosis level of F1, F2 or F3 (fibrosis in the absence of cirrhosis) and no diagnosis of chronic liver disease and elevated alanine aminotransferase (ALT) OR phenotypic diagnosis based on elevated ALT, BMI and diagnosis of Type 2 diabetes mellitus (DM)
- Part C patients: presence of NASH by histological evidence (liver biopsy obtained during the Screening period or 6 months or less prior to randomization) with fibrosis level of F2 or F3 and no diagnosis of chronic liver disease
And ( All Parts):
- ALT ≥ 43 IU/L (males) or ≥ 28 IU/L (females)
- Liver fat equal to or higher than 10% by MRI
Exclusion Criteria:
- previous exposure to OCA
- patients taking prohibited medications
- patients taking the following medicines UNLESS on a stable dose (within 25% of baseline dose) for at least 1 month before randomization: (for Part C patients, dose must be stable for at least 1 month prior to biopsy through Screening : anti- diabetic medications, insulin, beta-blockers, thiazide diuretics, fibrates, statins, niacin, ezetimibe, vitamin E (if doses > 200 IU/day; doses > 800 IU/day are prohibited), thyroid hormone, psychotropic medications, estrogen or estrogen containing birth control
- pregnant or nursing (lactating) women
- current or history of significant alcohol consumption for a period of more than 3 consecutive months within 1 year prior to screening
- uncontrolled diabetes mellitus
- new use of GLP-1 agonists such as liraglutide, exenatide, lixisenatide, albiglutide or dulaglutide within 3 months of screening
- presence of cirrhosis
- hepatic decompensation or severe liver impairment
- previous diagnosis of other forms of chronic liver disease
- patients with contraindications to MRI imaging
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02855164
Show 81 study locations
Documents provided by Novartis ( Novartis Pharmaceuticals ):
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Novartis Pharmaceuticals |
| ClinicalTrials.gov Identifier: | NCT02855164 |
| Other Study ID Numbers: |
CLJN452A2202 2015-005215-33 ( EudraCT Number ) |
| First Posted: | August 4, 2016 Key Record Dates |
| Results First Posted: | July 29, 2021 |
| Last Update Posted: | September 5, 2021 |
| Last Verified: | August 2021 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Undecided |
| Plan Description: | Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
|
LJN452 non-alcoholic steatohepatitis NASH |
phase 2 adaptive design randomized |
|
Fatty Liver Non-alcoholic Fatty Liver Disease Liver Diseases Digestive System Diseases |